New ‘peptoids’ show promise in resistant prostate cancer
A new generation of anti-androgen drugs such as Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Zytiga have increased survival... Read More
A new generation of anti-androgen drugs such as Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Zytiga have increased survival... Read More
Sophiris Bio has halted additional doses in an open-label study of topsalysin in prostate cancer, as it investigates the death... Read More
A transatlantic team of scientists led by the London-based Institute of Cancer Research (ICR) has made a major step towards... Read More
Years after winning a hotly anticipated FDA approval for its cancer immunotherapy Provenge—and struggling to build sales of the prostate... Read More
Myriad Genetics unveiled new data showing its prostate cancer diagnostic could accurately predict the 10-year risk of metastasis in men... Read More
Researchers have created a $65 test designed to show which prostate cancer patients will respond to Pfizer’s Xtandi and Johnson... Read More
Scientists at the University of Toronto have discovered a set of genetic mutations that they believe will help oncologists predict when... Read More